Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Tempest Therapeutics Leaps into IDO Development

Versant Ventures spinoff company Tempest Therapeutics secured $70 million in a Series B funding to advance the company’s immunotherapy pipeline.

Read More »

FDA working on a ‘dozen’ policies to boost copycat biotech drugs

The U.S. Food AND Drug Administration is working on around a dozen actions to boost use of cheaper versions of expensive biotech medicines, the head of the agency Scott Gottlieb said.

Read More »

Outcome Health And The Colorectal Cancer Alliance Announce Campaign To Support Patient Education

Outcome Health, a technology company that provides health education at the moment of care to improve patient outcomes, announced a partnership with the Colorectal Cancer Alliance to make patients aware of the signs and symptoms of colorectal cancer.

Read More »

Roche shares drop after deaths of patients taking Hemlibra

Roche’s shares dropped after the Swiss drugmaker told U.S.-based hemophilia advocacy groups that five patients treated with its medicine Hemlibra had died, while maintaining that the therapy was not the cause of the deaths.

Read More »

Tokyo court rejects Shire claim against Roche hemophilia drug

A Tokyo court ruled that Shire’s claim against Swiss drugmaker Roche’s new Hemlibra hemophilia medicine should be dismissed, Roche’s Japanese subsidiary Chugai said.

Read More »

AnaptysBio’s Mid-Stage Peanut Allergy Data Indicates Positive Results

Shares of AnaptysBio climbed after the company released positive interim data for its experimental peanut allergy treatment.

Read More »

FDA Accepts Bristol-Myers Combo Application

The U.S. Food and Drug Administration accepted Bristol-Myers Squibb’s supplemental Biologics License Application for Opdivo (nivolumab) with Yervoy (ipilimumab) for a type of colorectal cancer.

Read More »

Omnicom Health Group acquires Elsevier’s Pharma Communications business in Japan

Omnicom Health Group announced that it has entered into a definitive agreement to acquire the Pharma Communications business in Japan of Elsevier, part of RELX Group.

Read More »

After Spurning Pfizer, GlaxoSmithKline Cuts $13 Billion Deal with Novartis

GlaxoSmithKline opted to invest in its own consumer unit by acquiring the stake controlled by Swiss pharma giant Novartis.

Read More »

Clot-Busting Stroke Medicine: Mired in Controversy

An ischemic stroke occurs as a result of an obstruction within a blood vessel supplying blood to the brain and accounts for about 87 percent of all strokes, according to the American Stroke Association. A common treatment used to break up the clots and prevent brain damage has become mired in controversy.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2018 Focus: Top 50 Pharma, Company of the Year and more!


Ad Right Bottom